Sarepta Therapeutics (SRPT) News Today $116.79 -1.21 (-1.03%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Sarepta Therapeutics, Inc. (SRPT): A Bull Case TheoryJanuary 20 at 8:22 AM | insidermonkey.comSmith Salley Wealth Management Invests $889,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Smith Salley Wealth Management purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,308 shares of the biotechnology company'sJanuary 19 at 6:16 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Cut by Assenagon Asset Management S.A.Assenagon Asset Management S.A. reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 62.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,458 shares of the biotechnology companJanuary 18 at 3:40 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Earns "Sell" Rating from HC WainwrightJanuary 18 at 3:23 AM | americanbankingnews.comHC Wainwright Issues Positive Estimate for SRPT EarningsJanuary 18 at 2:14 AM | americanbankingnews.comFY2024 Earnings Forecast for SRPT Issued By HC WainwrightSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities researchers at HC Wainwright lifted their FY2024 earnings per share estimates for shares of Sarepta Therapeutics in a note issued to investors on Wednesday, January 15th. HC Wainwright analyst M. Kapoor now anticipates that the bioJanuary 17, 2025 | marketbeat.comSarepta Therapeutics: Guidance Suggests A Year Of Upside LikelyJanuary 16, 2025 | seekingalpha.comSarepta Therapeutics: Guidance Suggests A Year Of Upside LikelyJanuary 16, 2025 | seekingalpha.comTemporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta TherapeuticsJanuary 16, 2025 | markets.businessinsider.comSarepta Therapeutics: Strong Financial Performance and Promising Growth Prospects Justify Buy RatingJanuary 16, 2025 | markets.businessinsider.comWhat 14 Analyst Ratings Have To Say About Sarepta TherapeuticsJanuary 16, 2025 | benzinga.comHC Wainwright Reiterates "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT)HC Wainwright reiterated a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday.January 16, 2025 | marketbeat.comHC Wainwright Issues Optimistic Forecast for SRPT EarningsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report released on Wednesday, January 15th. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will poJanuary 16, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC WainwrightHC Wainwright restated a "sell" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.comStrong Financial Performance and Strategic Growth Plans Make Sarepta Therapeutics a Buy, Says Ritu BaralJanuary 15, 2025 | markets.businessinsider.comSarepta Therapeutics (NASDAQ:SRPT) Reports Strong Preliminary Financial Results for 2024January 15, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday.January 14, 2025 | marketbeat.comSarepta reports preliminary Q4 net product revenue $638.2MJanuary 14, 2025 | markets.businessinsider.comSarepta Therapeutics: Strong Elevidys Launch and Promising Pipeline Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comSarepta Therapeutics Tops 2024 Net Product Revenue GuidanceJanuary 13, 2025 | marketwatch.comSarepta Therapeutics Inc (SRPT) Reports Strong Preliminary Financial Results for 2024January 13, 2025 | gurufocus.comSarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product RevenueJanuary 13, 2025 | businesswire.comNordea Investment Management AB Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Nordea Investment Management AB lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 67,546 shares of the biotechnology cJanuary 10, 2025 | marketbeat.comResearch Analysts Set Expectations for SRPT Q1 EarningsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Investment analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report issued on Monday, January 6th. Zacks Research analyst S. Ganoria now expects that the biotechnolJanuary 9, 2025 | marketbeat.comMizuho Securities Remains a Buy on Sarepta Therapeutics (SRPT)January 9, 2025 | markets.businessinsider.comSarepta price target lowered to $165 from $182 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comHansa Biopharma to attend 2025 J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | prnewswire.comSarepta Therapeutics (SRPT) Gets a Buy from Bank of America SecuritiesJanuary 7, 2025 | markets.businessinsider.comSarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | finance.yahoo.comSarepta Therapeutics Inc (SRPT) to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comSarepta Therapeutics: Buy Rating Backed by Elevidys Growth and Diversified PipelineJanuary 2, 2025 | markets.businessinsider.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from AnalystsSarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twenty-two ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a holdJanuary 1, 2025 | marketbeat.comSarepta Therapeutics Grants Equity Awards to New EmployeesDecember 31, 2024 | gurufocus.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2024 | investing.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2024 | businesswire.comSarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Decreased by Principal Financial Group Inc.Principal Financial Group Inc. reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 26.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 267,037 shaDecember 24, 2024 | marketbeat.comSell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys ProjectionsDecember 20, 2024 | markets.businessinsider.comSarepta wins $115.2 million US drug patent verdict from Japan's Nippon ShinyakuDecember 20, 2024 | reuters.comHere are highlights from Thursday’s Analyst Blog:December 20, 2024 | finance.yahoo.comSarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC WainwrightHC Wainwright reaffirmed a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday.December 19, 2024 | marketbeat.comSarepta completes enrollment in the EMERGENE study of SRP-9003December 18, 2024 | markets.businessinsider.comSarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4December 18, 2024 | businesswire.comNational Bank of Canada FI Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)National Bank of Canada FI trimmed its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 94.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 387 shares of the biotechnology company'December 18, 2024 | marketbeat.comHans Lennart Rudolf Wigzell Sells 10,500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) StockDecember 17, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in StockSarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.December 16, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,696,354 shares of the biotechnology company'sDecember 16, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Stifel Financial CorpStifel Financial Corp grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,207 shares of the biotechnDecember 16, 2024 | marketbeat.comWorld Investment Advisors LLC Purchases Shares of 19,358 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)World Investment Advisors LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 19,358 shares of the biotechnology cDecember 15, 2024 | marketbeat.comSarepta Therapeutics, Inc. (SRPT): A Bull Case TheoryDecember 14, 2024 | insidermonkey.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.710.63▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼2311▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Summit Therapeutics News Today Genmab A/S News Today Viatris News Today Intra-Cellular Therapies News Today Moderna News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRPT Stock Alerts